A few words about us
Let us introduce ourselves
Fusion is a clinical stage company focused on developing novel targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers. Our first product, FPX-01, combines the precise targeting of a human experienced antibody with Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 to induce cancer cell death. A clinical trial on FPX-01 is planned for early 2018.